Top

Irish Journal of Medical Science (1971 -)

Published in:

01-12-2013 | Original Article

Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008

Authors: B. McGowan, K. Bennett, M. C. Casey, J. Doherty, C. Silke, B. Whelan

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2013

Abstract

Introduction

Poor adherence reduces the potential benefits of osteoporosis therapy, lowering gains in bone mineral density resulting in increased risk of fractures.

Aim

To compare prescribing and adherence patterns of anti-osteoporotic medications in patients admitted to an urban teaching hospital in Ireland with a fragility type fracture to patients admitted to a rural hospital in the North Western region.

Methodology

We identified all patients >55 years admitted to Sligo General Hospital between 2005 and 2008 with a fragility fracture (N = 744) using the hospital in-patient enquiry system (HIPE). The medical card number of those patients eligible for the primary care reimbursement services scheme (PCRS) facilitated the linkage of the HSE-PCRS scheme database to the HIPE database which enabled a study to identify persistence rates of patients prescribed osteoporosis therapy after discharge. The results were compared to the findings of a similar study carried out in St. James’s Hospital, Dublin.

Results

The 12 months post-fracture prescribing increased from 11.0 % (95 % CI 9.6, 12.4) in 2005 to 47 % (95 % CI 43.6, 50.3) in 2008 in the urban setting and from 25 % (95 % CI 21.5, 28.9) to 39 % (95 % CI 34.5, 42.7) in the rural setting. Adherence levels to osteoporosis medications at 12 months post-initiation of therapy was <50 % in both study groups. Patients on less frequent dosing regimes were better adherers.

Conclusion

The proportion of patients being discharged on anti-osteoporosis medications post-fragility fracture increased between 2005 and 2008 in both patient groups. Sub-optimal adherence levels to osteoporosis medications continue to be a major concern.

Available only for authorised users

Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11(8):669–674CrossRefPubMed

Johnell O, Kanis JA, Oden A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42 (Epub 2003 Oct 30)CrossRefPubMed

Lips P, Van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16(5):447–455 (Epub 2004 Dec 18)CrossRefPubMed

McGowan B, Casey MC, Silke C et al (2012) Hospitalizations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis. Osteoporos Int 24(3):849–857. doi:10.1007/s00198-012-2032-8 (Epub 2012 May 26)CrossRefPubMed

Report of the National Steering Group on the Prevention of Falls in Older People and the Prevention and Management of Osteoporosis throughout Life (2008). Strategy to Prevent Falls and Fractures in Ireland’s Ageing Population. 2008 January. Available from URL: http://www.hse.ie/eng/services/Publications/services/Older/Strategy_to_Prevent_Falls_and_Fractures_in_Ireland%E2%80%99s_Ageing_Population_-_Full_report.pdf, Accessed 20 May 2012

Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. doi:10.1007/s00198-012-2074-y (Epub 2012 Oct 19)CrossRefPubMed

Elliott-Gibson V, Bogoch ER, Jamal SA et al (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15(10):767–778 (Epub 2004 Jul 16)CrossRef

Fleurence RL, Iglesias CP, Torgerson DJ (2006) Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 17(1):29–40 (Epub 2005 Jun 25)CrossRefPubMed

Rabenda V, Vanoverloop J, Fabri V et al (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am. 90(10):2142–2148. doi:10.2106/JBJS.G.00864 CrossRefPubMed

10.

Zethraeus N, Borgstrom F, Strom O et al (2007) Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 38(6):922–928 (Epub 2005 Dec 5)

11.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38(6):922–928 (Epub 2005 Dec 5)CrossRefPubMed

12.

Imaz I, Zegarra P, Gonzalez-Enriquez J et al (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943–1951. doi:10.1007/s00198-009-1134-4 (Epub 2009 Dec 5)CrossRefPubMed

13.

Rabenda V, Hiligsmann M, Reginster J-Y (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10(14):2303–2315. doi:10.1517/14656560903140533 CrossRefPubMed

14.

Siris ES, Selby PL, Saag KG et al (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–S13. doi:10.1016/j.amjmed.2008.12.002 CrossRefPubMed

15.

Danese MD, Badamgarav E, Bauer DC (2009) Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 24(11):1819–1826. doi:10.1359/jbmr.090506 CrossRefPubMed

16.

Hiligsmann M, Rabenda V, Bruyere O et al (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2):170–177. doi:10.1016/j.healthpol.2010.01.014 (Epub 2010 Feb 13)CrossRefPubMed

17.

Hiligsmann M, Rabenda V, Gathon HJ et al (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210CrossRef

18.

Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48(2):380–388. doi:10.1016/j.bone.2010.09.012 (Epub 2010 Sep 17)CrossRefPubMed

19.

Hiligsmann M, McGowan B, Bennett K et al (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15(5):604–612. doi:10.1016/j.jval.2012.02.001 (Epub 2012 Apr 11)CrossRefPubMed

20.

Haynes RB, Ackloo E, Sahota N et al (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 16(2):CD000011. doi:10.1002/14651858.CD000011.pub3

21.

McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288(22):2868–2879CrossRefPubMed

22.

Hiligsmann M, Ravenda V, Bruyere O et al (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2):170–177. doi:10.1016/j.healthpol.2010.01.014 (Epub 2010 Feb 13)CrossRefPubMed

23.

Patrick AR, Schousboe JT, Losina E et al (2011) The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab 96(9):2762–2770. doi:10.1210/jc.2011-0575 (Epub 2011 Jul 6)CrossRefPubMed

24.

Copher C, Buzinec P, Zarotsky V et al (2010) Physician perception of patient adherence to osteoporosis medications from pharmacy claims. Curr Med Res Opin 26(4):777–785. doi:10.1185/03007990903579171 CrossRefPubMed

25.

Iversen MD, Vora RR, Servi A et al (2011) Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 34(2):72–81. doi:10.1097/JPT.0b013e3181ff03b4 PubMed

26.

International Osteoporosis Foundation (2005) The adherence gap: why osteoporosis patients don’t continue with treatment. www.iofbonehealthorg/download/ostefound/filemanager/publications/pdf/adherence_gap_reportpdf, Accessed 26 May 2012

27.

Elwyn G, Edwards A, Britten N (2003) What information do patients need about medicines? “Doing prescribing”: how doctors can be more effective. BMJ 327(7419):864–867CrossRefPubMed

28.

Lewis DK, Robinson J, Wilkinson E (2003) Factors involved in deciding to start preventive treatment: qualitative study of clinicians’ and lay people’s attitudes. BMJ 327(7419):841CrossRefPubMed

29.

Louviere JJ, Islam T (2008) A comparison of importance weights and willingness-to-pay measures derived from choice-based conjoint, constant sum scales and best-worst scaling. J Bus Res 61(9):903–911CrossRef

30.

Elwyn G, O’Connor A, Stacey D et al (2006) Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 333(7565):417 (Epub 2006 Aug 14)CrossRefPubMed

31.

Elwyn G, Kreuwel I, Durand MA et al (2011) How to develop web-based decision support interventions for patients: a process map. Patient Educ Couns 82(2):260–265. doi:10.1016/j.pec.2010.04.034 (Epub 2010 Jun 2)CrossRefPubMed

32.

McGowan B, Bennett K, Marry J, Walsh JB, Casey MC (2012) Patient profile in a bone health and osteoporosis prevention service in Ireland. IJMS 181(4):511–515. doi:10.1007/s11845-012-0806-9 (Epub 2012 Feb 29)CrossRef

Title: Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008
Authors: B. McGowan
K. Bennett
M. C. Casey
J. Doherty
C. Silke
B. Whelan
Publication date: 01-12-2013
Publisher: Springer London
Published in: Irish Journal of Medical Science (1971 -) / Issue 4/2013
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-013-0935-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Aim

Methodology

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

Basic surgical training in Ireland: the impact of operative experience, training program allocation and mentorship on trainee satisfaction

Tumor suppressive miR-509-5p contributes to cell migration, proliferation and antiapoptosis in renal cell carcinoma

Patient-reported quality-of-life after radiofrequency ablation of varicose veins compared to conventional surgery

Does the cost of care differ for patients with fee-for-service vs. capitation of payment? A case–control study in gastroenterology

A cross-sectional observation of burnout in a sample of Irish junior doctors

The otolaryngology, head and neck training appraisal questionnaire: a national general practice perspective

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials